SignalXSignalX

CYTOKINETICS INC (CYTK) Q3 2025 10-Q Quarterly Report

Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
CYTOKINETICS INC Overview

CYTOKINETICS INC (CYTK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

CYTOKINETICS INC Q3 2025 10-Q Analysis

Risk Factors

  • • New regulatory risk: FDA workforce reductions and government shutdowns may delay NDA approval this quarter, with aficamten PDUFA date extended to Dec 26, 2025
  • • Updated clinical risk: discontinuation of COURAGE-ALS Phase 3 trial due to futility signals increased uncertainty in drug efficacy demonstration
  • • Legal/compliance risk: potential FDA-required companion diagnostic for omecamtiv mecarbil depends on third-party Microgenics' success in regulatory clearance and manufacturing
  • • Near-term operational risk: enrollment challenges in clinical trials caused by competing therapies and patient retention could delay development timelines
  • • Financial risk: new U.S. tariffs including 10% global baseline and 125% China tariffs may increase raw material costs, impacting contract manufacturing expenses

CYTOKINETICS INC Q3 2025 Quarterly Financials
XBRL

Revenue

$2M

▲ +318.1% YoY▼ -97.1% QoQ

Net Income

-$306M

▼ -90.7% YoY▼ -127.9% QoQ

Operating Margin

-8613.4%

▲ +2179721bp YoY▼ -844638bp QoQ

Net Margin

-15815.0%

▲ +1885997bp YoY▼ -1561373bp QoQ

ROE

58.8%

Total Assets

$1.4B

EPS (Diluted)

$-2.55

▼ -86.1% YoY▼ -125.7% QoQ

Operating Cash Flow

-$108M

▼ -5.9% YoY▲ +16.2% QoQ

Source: XBRL data from CYTOKINETICS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on CYTOKINETICS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.